Your browser doesn't support javascript.
loading
The European Particle Therapy Network (EPTN) consensus on the follow-up of adult patients with brain and skull base tumours treated with photon or proton irradiation.
De Roeck, Laurien; van der Weide, Hiska L; Eekers, Daniëlle B P; Kramer, Miranda C; Alapetite, Claire; Blomstrand, Malin; Burnet, Neil G; Calugaru, Valentin; Coremans, Ida E M; Di Perri, Dario; Harrabi, Semi; Iannalfi, Alberto; Klaver, Yvonne L B; Langendijk, Johannes A; Romero, Alejandra Méndez; Paulsen, Frank; Roelofs, Erik; de Ruysscher, Dirk; Timmermann, Beate; Vitek, Pavel; Weber, Damien C; Whitfield, Gillian A; Nyström, Petra Witt; Zindler, Jaap; Troost, Esther G C; Lambrecht, Maarten.
Afiliación
  • De Roeck L; KU Leuven, University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Belgium; University Hospitals Leuven, Department of Radiation Oncology, Belgium. Electronic address: Laurien.deroeck@uzleuven.be.
  • van der Weide HL; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands.
  • Eekers DBP; Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, The Netherlands.
  • Kramer MC; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands.
  • Alapetite C; Institut Curie, Radiation Oncology Department, Paris & Proton Center, Orsay, France.
  • Blomstrand M; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Burnet NG; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Calugaru V; Institute Curie, Paris, France; Institute Curie, Centre de Protonthérapie d'Orsay, Orsay, France.
  • Coremans IEM; Leiden University Medical Centre, Department of Radiotherapy, The Netherlands; Holland Proton Therapy Centre, Delft, The Netherlands.
  • Di Perri D; Department of Radiation Oncology, Cliniques universitaires Saint-Luc, Brussels, Belgium; Particle Therapy Interuniversitary Center Leuven (PartICLe), Belgium.
  • Harrabi S; Heidelberg Ion-Beam Therapy Centre (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
  • Iannalfi A; National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
  • Klaver YLB; Holland Proton Therapy Centre, Delft, The Netherlands.
  • Langendijk JA; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands.
  • Romero AM; Holland Proton Therapy Centre, Delft, The Netherlands; Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Paulsen F; Department of Radiation Oncology, Eberhard-Karls-Universität Tübingen, Germany.
  • Roelofs E; Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, The Netherlands.
  • de Ruysscher D; Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, The Netherlands.
  • Timmermann B; Clinic for Particle Therapy, University Hospital Essen, West German Cancer Center (WTZ), Germany; West German Proton Therapy Center Essen (WPE), Germany; German Cancer Consortium (DKTK), partnersite Essen, Germany.
  • Vitek P; Proton Therapy Center Czech, Prague, Czech Republic.
  • Weber DC; Paul Scherrer Institut Center for Proton Therapy, ETH Domain, Villigen, Switzerland.
  • Whitfield GA; The University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, United Kingdom; The Children's Brain Tumour Research Network, University of Manchester, Royal Manchester Children's Hospital, United Kingdom.
  • Nyström PW; Danish Centre for Particle Therapy, Aarhus, Denmark; Norwegian Radiation and Nuclear Safety Authority, Oslo, Norway.
  • Zindler J; Holland Proton Therapy Centre, Delft, The Netherlands; Haaglanden Medisch Centrum, Department of Radiotherapy, Leidschendam, The Netherlands.
  • Troost EGC; German Cancer Consortium (DKTK), partnersite Essen, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Institute of Radiooncology - OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Germany;
  • Lambrecht M; KU Leuven, University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Belgium; University Hospitals Leuven, Department of Radiation Oncology, Belgium; Particle Therapy Interuniversitary Center Leuven (PartICLe), Belgium; Leuven Kanker Instituut (LKI), UZ Leuven Gasthuisbe
Radiother Oncol ; 168: 241-249, 2022 03.
Article en En | MEDLINE | ID: mdl-35093408
ABSTRACT

PURPOSE:

Treatment-related toxicity after irradiation of brain tumours has been underreported in the literature. Furthermore, there is considerable heterogeneity on how and when toxicity is evaluated. The aim of this European Particle Network (EPTN) collaborative project is to develop recommendations for uniform follow-up and toxicity scoring of adult brain tumour patients treated with radiotherapy.

METHODS:

A Delphi method-based consensus was reached among 24 international radiation-oncology experts in the field of neuro-oncology concerning the toxicity endpoints, evaluation methods and time points.

RESULTS:

In this paper, we present a basic framework for consistent toxicity scoring and follow-up, using multiple levels of recommendation. Level I includes all recommendations that are considered minimum of care, whereas level II and III are optional evaluations in the advanced clinical or research setting, respectively. Per outcome domain, the clinical endpoints and evaluation methods per level are listed. Where relevant, the organ at risk threshold doses for recommended referral to specific organ specialists are defined.

CONCLUSION:

These consensus-based recommendations for follow-up will enable the collection of uniform toxicity data of brain tumour patients treated with radiotherapy. With adoptation of this standard, collaboration will be facilitated and we can further propel the research field of radiation-induced toxicities relevant for these patients. An online tool to implement this guideline in clinical practice is provided at www.cancerdata.org.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Base del Cráneo / Terapia de Protones Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Radiother Oncol Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Base del Cráneo / Terapia de Protones Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Radiother Oncol Año: 2022 Tipo del documento: Article
...